发帖
每发1个新帖
可以获得0.5个丁当奖励
回帖

【文摘发布】活体供肝移植及尸体供肝移植后肝癌复发与死亡情况

只看楼主
页码直达：
直达末页

楼主

丁香园准中级站友

1楼

这个帖子发布于13年零218天前，其中的信息可能已发生改变或有所发展。

Title:Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.

Author:Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL

source:Am J Transplant. 2007 Jun;7(6):1601-8.

IF:6.002(2005)

We examined mortality and recurrence of hepatocellular carcinoma (HCC) among 106 transplant candidates with cirrhosis and HCC who had a potential living donor evaluated between January 1998 and February 2003 at the nine centers participating in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Cox regression models were fitted to compare time from donor evaluation and time from transplant to death or HCC recurrence between 58 living donor liver transplant (LDLT) and 34 deceased donor liver transplant (DDLT) recipients. Mean age and calculated Model for End-Stage Liver Disease (MELD) scores at transplant were similar between LDLT and DDLT recipients (age: 55 vs. 52 years, p = 0.21; MELD: 13 vs. 15, p = 0.08). Relative to DDLT recipients, LDLT recipients had a shorter time from listing to transplant (mean 160 vs. 469 days, p < 0.0001) and a higher rate of HCC recurrence within 3 years than DDLT recipients (29% vs. 0%, p = 0.002), but there was no difference in mortality or the combined outcome of mortality or recurrence. LDLT recipients had lower relative mortality risk than patients who did not undergo LDLT after the center had more experience (p = 0.03). Enthusiasm for LDLT as HCC treatment is dampened by higher HCC recurrence compared to DDLT.

邀请讨论

搜索

2007-06-15 10:31 浏览 : 1087 回复 : 6

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 分享一例新型冠状病毒肺炎从入院到出院影像学变化

wcj902

普外科

常驻站友

2楼

本人认领了，48小时后如果没有回复的话请其他网友认领

2007-06-15 17:51

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 选择哪个内科方向

yoyololo

急诊科

丁香园中级站友

3楼

继续认领。48小时后如果没有回复的话请其他网友认领。

2007-06-18 22:56

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

• 教育部：今年国家定向培养免费医学生，你会报考吗？——回帖

yoyololo

急诊科

丁香园中级站友

4楼

初译： （非常感谢楼主赐教！此稿是修改稿）

Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation.
活体供肝移植及尸体供肝移植后肝癌的复发与死亡

We examined mortality and recurrence of hepatocellular carcinoma (HCC) among 106 transplant candidates with cirrhosis and HCC who had a potential living donor evaluated between January 1998 and February 2003 at the nine centers participating in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL).
我们从106名肝硬化和肝癌的移植患者中分析了肝癌(HCC)的致死率和复发性，这些患者是从1998年1月到2003年2月，由9个参与成人——成人活体供肝移植队列研究（A2ALL）的中心提供的可能做过活体供肝移植的人群。

Cox regression models were fitted to compare time from donor evaluation and time from transplant to death or HCC recurrence between 58 living donor liver transplant (LDLT) and 34 deceased donor liver transplant (DDLT) recipients.
在58例活体供肝移植（LDLT）和34例尸体供肝移植(DDLT)受者中，应用Cox回归模型分析可以对待肝时间以及对移植后死亡或肝癌复发的时间进行评估。

Mean age and calculated Model for End-Stage Liver Disease (MELD) scores at transplant were similar between LDLT and DDLT recipients (age: 55 vs. 52 years, p = 0.21; MELD: 13 vs. 15, p = 0.08).
LDLT和DDLT受者的平均年龄和终末期肝病（MELD）模型评分相似。（年龄：55vs 52，p = 0.21; MELD: 13 vs. 15, p = 0.08）

Relative to DDLT recipients, LDLT recipients had a shorter time from listing to transplant (mean 160 vs. 469 days, p < 0.0001) and a higher rate of HCC recurrence within 3 years than DDLT recipients (29% vs. 0%, p = 0.002), but there was no difference in mortality or the combined outcome of mortality or recurrence.
与DDLT受者相比，LDLT受者待肝时间较短（平均160vs 469天，p < 0.0001），而3年内肝癌的复发率要比DDLT受者高 (29% vs 0%, p = 0.002)，但是致死率、终点事件（死亡或复发）发生率没有区别。

LDLT recipients had lower relative mortality risk than patients who did not undergo LDLT after the center had more experience (p = 0.03). Enthusiasm for LDLT as HCC treatment is dampened by higher HCC recurrence compared to DDLT.
根据（移植）中心丰富的经验：LDLT受者的相对死亡风险要比没有做LDLT的患者低(p = 0.03)。由于LDLT相对DDLT而言有较高的肝癌复发率，因此对其治疗肝癌的热情也随之减弱。

＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝＝
再次感谢楼主及时给予的帮助！

2007-06-19 17:56

投票
收藏
打赏
引用
分享
- 微信扫一扫
- 新浪微博
- 丁香客
- 复制网址
举报
- 广告宣传推广
- 政治敏感、违法虚假信息
- 恶意灌水、重复发帖
- 违规侵权、站友争执
- 附件异常、链接失效
- 其他

yoyololo 编辑于 2007-06-19 22:42

• 综合医院全科门诊中乏力患者特征及就诊原因分析

科技动态

【文摘发布】活体供肝移植及尸体供肝移植后肝癌复发与死亡情况

提示

丁香园旗下网站

关于丁香园

官方链接

科技动态

分享到：

微信扫一扫

【文摘发布】活体供肝移植及尸体供肝移植后肝癌复发与死亡情况

微信扫一扫

微信扫一扫

微信扫一扫

微信扫一扫

提示

丁香园旗下网站

关于丁香园

官方链接